Optimism Bias in the Design of Phase III Randomized Control Trials Evaluating PD-1/PD-L1 Targeting Monoclonal Antibodies

BACKGROUND: Many randomized control trials (RCTs) evaluating programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) targeting monoclonal antibodies (mAbs) have been completed or are in progress. We examined hypothesized hazard ratios (HHRs) and observed hazard ratios (OHRs) from publis...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Showbaki, Laith, Almugbel, Fahad A, Alqaisi, Husam A, Amir, Eitan, Chen, Eric X
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
New Drug Development and Clinical Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177107/
https://www.ncbi.nlm.nih.gov/pubmed/35278074
http://dx.doi.org/10.1093/oncolo/oyac031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177107/
https://www.ncbi.nlm.nih.gov/pubmed/35278074
http://dx.doi.org/10.1093/oncolo/oyac031

Ejemplares similares